BPC-157
Also known as Body Protection Compound-157 · PL 14736 · Bepecin
New
Reconstitution & dosing guide
2 mg · 5 mg · 10 mg vial sizes — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
BPC 157 (BC10) · Not in current stock
$80 / vial
2mg x 10 vials
BPC 157 (BC2) · Not in current stock
$20 / vial
5mg x 10 vials
BPC 157 (BC5) · Not in current stock
$20 / vial
500mcg x 100
BPC-157 Capsules · Not in current stock
$20 / vial
Prices per vial · Research use only · Not medical advice.
Synthetic gastric pentadecapeptide studied for tissue repair, gut integrity, and soft-tissue recovery.
How to picture it
Picture a construction site where the roads to the damaged area are washed out and the workers are stressed. BPC-157 is studied as a local repair signal that helps open supply routes (angiogenesis research), balances nitric-oxide pathway chemistry, and supports cytoprotection — keeping cells from quitting under stress. Across tendon, gut, muscle, and other injury models, the picture is a field medic for soft tissue and barrier integrity: improve blood supply, calm local chaos, and support structural repair. It is not a painkiller and not a steroid; it is a multi-tissue recovery concept with a broad preclinical footprint.
Research focus & benefits
- Tendon, ligament, and soft-tissue healing signals in animal models
- Gut barrier and ulcer-protection research interest
- Angiogenesis and cytoprotective pathway studies
- Muscle and wound recovery contexts in preclinical literature
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
BPC-157 is a 15-amino-acid peptide derived from a protective protein found in human gastric juice. In preclinical research it has been associated with accelerated healing of tendons, ligaments, muscle, bone, and intestinal tissue. It is one of the most discussed compounds in the biohacking recovery community, though robust large-scale human trials remain limited and regulatory status has tightened in several markets.
Mechanism
Proposed actions include modulation of the nitric oxide system, upregulation of growth-factor signaling (including VEGFR2 pathways), stabilization of the gut barrier, and influence on the brain-gut axis. It may support angiogenesis and fibroblast activity in injury models.
Research uses
- Tendon and ligament injury models
- Inflammatory bowel / gut barrier research
- Muscle crush and bone healing models
- Neuroprotection in animal studies
Research dosing notes
Community research protocols commonly discuss microgram-range subcutaneous dosing near an injury site or abdomen, and sometimes oral capsules for gut-focused goals. There is no established clinical dosing standard for general use.
Half-life / kinetics
Short (hours); often dosed once or twice daily in research protocols
Common research routes
Reported considerations
- Generally described as well-tolerated in anecdotal reports
- Injection-site irritation
- Unknown long-term human safety profile
Contraindications / cautions
- Active malignancy concerns (theoretical angiogenesis effects)
- Pregnancy and breastfeeding
- Anyone requiring evidence-based medical therapy for serious injury
Common research stacks
- TB-500 (Wolverine stack)
- GHK-Cu
- CJC-1295 / Ipamorelin
Legal / access note
Not FDA-approved for human use. FDA has raised concerns about compounding certain bulk peptides including BPC-157. Often sold as a research chemical.